Idenix Pharmaceuticals Inc. believes it is finally positioned to become a player in the race for an all-oral HCV regimen after restructuring its nine-year old collaboration with Novartis AG. But by now several large HCV companies have made their plays.

The deal amendment announced last week terminates Novartis' option to license current and future Idenix compounds.